Marek J LosMarek Los studied medicine at Jagiellonian Univ., Krakow, Poland. He obtained his doctoral degree from Univ. Heidelberg, in 1995, and habilitation (academic teaching license) in Molecular Medicine, from Univ. Muenster in 2002. He is currently the hea of Department of Molecular Biology, Faculty of Pharmacy, Silesian University of Medicine, in Katowice, Poland. He is also assoc. editor at The European Journal of Pharmacology, holds 2 Visiting Professorships at other Polish universities, and a 'Senior Scientific Adviser' position at Linkocare AB, Linköping, Sweden. Linkocare's core business is the production of artificial corneas. Dr. Los (co-)authors about 150 scientific papers, some of them highly-cited, edited several books and volumes. He has been serving as member of a number of editorial boards of scientific journals, as well as on various grant review committees in the Europe and in Canada. Dr. Los pursues various research projects within area of oncology, targeted cancer therapies and Regenerative Medicine. His most important scientific achievements were the description of involvement of caspase family of proteases in CD95 (APO-1/Fas) mediated apoptosis, (Los et al., 1995; Nature 375: 81-83), and the discovery of the role of kinase Akt both in the regulation of cell survival and cell death of cancer cells (Maddika et al., 2008, J. Cell Sci.; Maddika et al., 2009, Mol. Cell. Biol.). His research interest encompasses cancer immunology, cell death execution pathways, as well as cancer stem cell biology, epigenetic reprogramming (production of iPS-cells), as well as transdifferentiation technologies. Read More Read Less